Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 02, 2023 07:00 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

STAMFORD, Conn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
July 24, 2023 07:00 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023

STAMFORD, Conn., July 24, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
June 01, 2023 07:00 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics to Present at the Jefferies Healthcare Conference

STAMFORD, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
May 18, 2023 02:00 ET | Source: Cara Therapeutics, Inc.

Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that...
May 15, 2023 16:01 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics Reports First Quarter 2023 Financial Results

– 1Q23 total revenue of $6.2M including collaborative revenue of $2.8M from the Company’s share of profit of KORSUVA® (difelikefalin) injection – – Acceleration in demand for KORSUVA injection as...
May 01, 2023 07:00 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023

STAMFORD, Conn., May 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
April 10, 2023 07:00 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference

STAMFORD, Conn., April 10, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
March 14, 2023 07:00 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report

STAMFORD, Conn., March 14, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
March 06, 2023 16:01 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

– 4Q22 total revenue was $3.3 million including collaborative revenue of $1.1 million from the Company’s share of profit of KORSUVA® (difelikefalin) injection; FY22 revenue was $41.9 million including...
February 21, 2023 07:00 ET | Source: Cara Therapeutics, Inc.

Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

STAMFORD, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...